{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:09:45Z","timestamp":1792462185049,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Daxocox\u00ae [Ecuphar\/Animalcare Group] contains the selective COX-2 inhibitor enflicoxib, approved in the EU for the treatment of pain and inflammation associated with osteoarthritis in dogs. The safety of Daxocox<jats:sup>\u00ae<\/jats:sup> was evaluated in a target animal safety study: Groups of 4 dogs per sex each were treated once weekly with placebo or Daxocox tablets at 1-, 3- and 5-times (1X, 3X and 5X) the maximum recommended therapeutic dose of enflicoxib (0, 4, 12 or 20\u2009mg\/kg, respectively). After an initial loading dose, dogs in the placebo control, 1X and 3X groups were administered for 32\u2009weeks, and those in the 5X group were administered for 13\u2009weeks. Dogs were subjected to daily food consumption measurements and clinical and dose observations. Body weight measurements, physical examinations, clinical pathology, urinalysis, faecal occult blood (FOB) and electrocardiographic (ECG) and blood pressure measurements, buccal mucosal bleeding time (BMBT), ophthalmology and gastroduodenal endoscopy examinations were conducted throughout the study.\u00a0At study completion, all dogs were subjected to gross necropsy. Histopathology was performed on selected tissues from all animals in all groups. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No clinical signs were noted, and no toxicologically relevant dose-associated effects were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Results show that Daxocox\u00ae is well-tolerated and has a broad safety margin when administered as directed in dogs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12917-021-02910-0","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T08:03:03Z","timestamp":1622707383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term safety evaluation of Daxocox\u00ae tablets (enflicoxib) in dogs after weekly oral administrations for seven months"],"prefix":"10.1186","volume":"17","author":[{"given":"Josep","family":"Homedes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Salichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"issue":"3","key":"2910_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/0022-5193(63)90004-3","volume":"4","author":"L Angervall","year":"1963","unstructured":"Angervall L, Carlstr\u00f6m E. Theoretical criteria for the use of relative organ weights and similar ratios in biology. J Theor Biol. 1963;4(3):254\u20139. https:\/\/doi.org\/10.1016\/0022-5193(63)90004-3 PMID: 5875198.","journal-title":"J Theor Biol"},{"key":"2910_CR2","doi-asserted-by":"crossref","unstructured":"Bannwarth B. Tolerance gastro-intestinale des anti-inflammatoires non-st\u00e9ro\u00efdiens [gastrointestinal tolerance of nonsteroidal anti-inflammatory agents]. Drugs. 2000;59 spec no 1:17-23. French. PMID: 10841069.","DOI":"10.2165\/00003495-200059991-00003"},{"key":"2910_CR3","first-page":"268","volume":"160","author":"MS Bartlett","year":"1937","unstructured":"Bartlett MS. Properties of sufficiency and statistical tests. Proc Royal Soc Series A. 1937;160:268\u201382.","journal-title":"Proc Royal Soc Series A"},{"issue":"5","key":"2910_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1892\/0891-6640(2005)19[633:tcnpca]2.0.co;2","volume":"19","author":"MS Bergh","year":"2005","unstructured":"Bergh MS, Budsberg SC. The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med. 2005;19(5):633\u201343. https:\/\/doi.org\/10.1892\/0891-6640(2005)19[633:tcnpca]2.0.co;2.","journal-title":"J Vet Intern Med"},{"key":"2910_CR5","unstructured":"Directive 2004\/10\/EC of the European parliament and of the council of 11 February 2004 on THE harmonisation of laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their applications for tests on chemical substances. https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2004:050:0044:0059:EN:PDF. Accessed 23 Mar 2020."},{"issue":"272","key":"2910_CR6","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","volume":"50","author":"CW Dunnett","year":"1955","unstructured":"Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50(272):1096\u2013121. https:\/\/doi.org\/10.1080\/01621459.1955.10501294.","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"2910_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2307\/2528490","volume":"20","author":"CW Dunnett","year":"1964","unstructured":"Dunnett CW. New tables for multiple comparisons with a control. Biometrics. 1964;20(3):482\u201391. https:\/\/doi.org\/10.2307\/2528490.","journal-title":"Biometrics"},{"key":"2910_CR8","unstructured":"Fisher RA. Statistical Methods for Research Workers, 14th edn., p.96. Hafner Publishing Company, New York, USA. 1973."},{"issue":"6","key":"2910_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/0300985813485099","volume":"50","author":"KN Gibson-Corley","year":"2013","unstructured":"Gibson-Corley KN, Olivier AK, Meyerholz DK. Principles for valid histopathologic scoring in research. Vet Pathol. 2013;50(6):1007\u201315. https:\/\/doi.org\/10.1177\/0300985813485099.","journal-title":"Vet Pathol"},{"issue":"4","key":"2910_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2460\/javma.2004.225.533","volume":"225","author":"VA Hampshire","year":"2004","unstructured":"Hampshire VA, Doddy FM, Post LO, Koogler TL, Burgess TM, Batten PO, et al. Adverse drug event reports at the United States food and drug Administration Center for Veterinary Medicine. J Am Vet Med Assoc. 2004;225(4):533\u20136. https:\/\/doi.org\/10.2460\/javma.2004.225.533 PMID: 15344359.","journal-title":"J Am Vet Med Assoc"},{"issue":"10","key":"2910_CR11","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.intimp.2010.07.013","volume":"10","author":"MA I\u00f1iguez","year":"2010","unstructured":"I\u00f1iguez MA, Punz\u00f3n C, Cacheiro-Llaguno C, D\u00edaz-Mu\u00f1oz MD, Duque J, Cuberes R, et al. Cyclooxygenase-independent inhibitory effects on T cell activation of novel 4,5-dihydro-3 trifluoromethyl pyrazole cyclooxygenase-2 inhibitors. Int Immunopharmacol. 2010;10(10):1295\u2013304. https:\/\/doi.org\/10.1016\/j.intimp.2010.07.013.","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"2910_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/vr.c97","volume":"166","author":"JF Innes","year":"2010","unstructured":"Innes JF, Clayton J, Lascelles BDX. Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis. Vet Rec. 2010;166(8):226\u201330. https:\/\/doi.org\/10.1136\/vr.c97.","journal-title":"Vet Rec"},{"key":"2910_CR13","doi-asserted-by":"publisher","unstructured":"Luna SPL, Bas\u0131\u2019lio AC, Steagall PVM, et al. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res 2007;68(3):258\u2013264. https:\/\/doi.org\/10.2460\/ajvr.68.3.258.","DOI":"10.2460\/ajvr.68.3.258"},{"issue":"6","key":"2910_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.cvsm.2018.06.003","volume":"48","author":"MK McLean","year":"2018","unstructured":"McLean MK, Khan SA. Toxicology of frequently encountered nonsteroidal anti-inflammatory drugs in dogs and cats: an update. Vet Clin North Am Small Anim Pract. 2018;48(6):969\u201384. https:\/\/doi.org\/10.1016\/j.cvsm.2018.06.003.","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"6","key":"2910_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.cvsm.2019.07.009","volume":"49","author":"B Monteiro","year":"2019","unstructured":"Monteiro B, Steagall PV. Antiinflammatory drugs. Vet Clin North Am Small Anim Pract. 2019;49(6):993\u20131011. https:\/\/doi.org\/10.1016\/j.cvsm.2019.07.009.","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"5","key":"2910_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/jvim.12127","volume":"27","author":"BP Monteiro-Steagall","year":"2013","unstructured":"Monteiro-Steagall BP, Steagall PV, Lascelles BD. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med. 2013;27(5):1011\u20139. https:\/\/doi.org\/10.1111\/jvim.12127.","journal-title":"J Vet Intern Med"},{"issue":"11","key":"2910_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/vr.152.11.323","volume":"152","author":"M Moreau","year":"2003","unstructured":"Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec. 2003;152(11):323\u20139. 12665145. https:\/\/doi.org\/10.1136\/vr.152.11.323.","journal-title":"Vet Rec."},{"key":"2910_CR18","unstructured":"OECD (Organisation for Economic Cooperation and Development) Principles of Good Laboratory Practice (GLP) and Compliance Monitoring (as revised in 1997), ENV\/MC\/CHEM (98)17 http:\/\/www.oecd.org\/officialdocuments\/publicdisplaydocumentpdf\/?cote=env\/mc\/chem(98)17&doclanguage=en."},{"issue":"6","key":"2910_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/bdd.258","volume":"22","author":"RF Reinoso","year":"2001","unstructured":"Reinoso RF, Farr\u00e1n R, Morag\u00f3n T, Garc\u00eda-Soret A, Mart\u00ednez L. Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs. Biopharm Drug Dispos. 2001;22(6):231\u201342. https:\/\/doi.org\/10.1002\/bdd.258.","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"2910_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2307\/2529789","volume":"33","author":"E Shirley","year":"1977","unstructured":"Shirley E. A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. Biometrics. 1977;33(2):386\u20139. 884197. https:\/\/doi.org\/10.2307\/2529789.","journal-title":"Biometrics."},{"issue":"7","key":"2910_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.4155\/fmc.11.35","volume":"3","author":"JS Schofield","year":"2011","unstructured":"Schofield JS. Animal-health pharmaceuticals: research responsibilities and efforts in target animal safety and laboratory animal welfare. Future Med Chem. 2011;3(7):851\u20134. https:\/\/doi.org\/10.4155\/fmc.11.35.","journal-title":"Future Med Chem"},{"issue":"3","key":"2910_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1365-2885.2007.00842.x","volume":"30","author":"PV Steagall","year":"2007","unstructured":"Steagall PV, Mantovani FB, Ferreira TH, Salcedo ES, Moutinho FQ, Luna SP. Evaluation of the adverse effects of oral firocoxib in healthy dogs. J Vet Pharmacol Ther. 2007;30(3):218\u201323. https:\/\/doi.org\/10.1111\/j.1365-2885.2007.00842.x.","journal-title":"J Vet Pharmacol Ther"},{"issue":"4","key":"2910_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2307\/2527654","volume":"15","author":"RGD Steel","year":"1959","unstructured":"Steel RGD. A multiple comparison rank sum test: treatments versus control. Biometrics. 1959;15(4):560\u201372. https:\/\/doi.org\/10.2307\/2527654.","journal-title":"Biometrics"},{"key":"2910_CR24","unstructured":"UK Animals (Scientific Procedures) Act 1986 http:\/\/www.legislation.gov.uk\/ukpga\/1986\/14\/contents. Amendment Regulations 2012 (the Act) Accessed 20 Mar 2020."},{"key":"2910_CR25","unstructured":"UK Good Laboratory Practice Regulations (Statutory Instrument 1999 No. 3106, as amended by Statutory Instrument 2004 No. 994). http:\/\/www.legislation.gov.uk\/uksi\/2004\/994\/pdfs\/uksi_20040994_en.pdf Accessed 23\/03\/2020."},{"key":"2910_CR26","unstructured":"UK Home Office Code of Practice for the Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes Presented to Parliament pursuant to Section 21 (5) of the Animals (Scientific Procedures) Act 1986. December 2014 https:\/\/assets.publishing.service.gov.uk\/ government\/uploads\/system\/uploads\/attachment_data\/file\/388535\/CoPanimalsWeb.pdf. Accessed 23\/03\/2020."},{"key":"2910_CR27","unstructured":"VICH (Veterinary International Conference on Harmonization) Guideline 43: Target Animal Safety for Veterinary Pharmaceutical Products. 2008. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/vich-gl43-target-animal-safety-veterinary-pharmaceutical-products-step-7_en.pdf. Accessed 20 Mar 2020."},{"key":"2910_CR28","unstructured":"VMD (Veterinary Medicines Directorate). Product Information Database. Daxocox 15 mg Tablets for Dogs. Product Details. 2021. https:\/\/www.vmd.defra.gov.uk\/productinformationdatabase\/files\/SPC_Documents\/SPC_2050494.PDF"},{"issue":"1","key":"2910_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1593\/tlo.08160","volume":"2","author":"M Wagemakers","year":"2009","unstructured":"Wagemakers M, van der Wal GE, Cuberes R, \u00c1lvarez I, Andr\u00e9s EM, Buxens J, et al. COX-2 inhibition combined with radiation reduces Orthotopic Glioma outgrowth by targeting the tumor vasculature. Transl Oncol. 2009;2(1):1\u20137. https:\/\/doi.org\/10.1593\/tlo.08160.","journal-title":"Transl Oncol"},{"issue":"11","key":"2910_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1136\/vr.102435","volume":"175","author":"MB Walton","year":"2014","unstructured":"Walton MB, Cowderoy EC, Wustefeld-Janssens B, Lascelles BD, Innes JF. Mavacoxib and meloxicam for canine osteoarthritis: a randomised clinical comparator trial. Vet Rec. 2014;175(11):280. https:\/\/doi.org\/10.1136\/vr.102435 Epub 2014 May 23. PMID: 24859353.","journal-title":"Vet Rec"},{"issue":"1","key":"2910_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1939-1676.2009.0443.x","volume":"24","author":"RJ Washabau","year":"2010","unstructured":"Washabau RJ, Day MJ, Willard MD, et al. Endoscopic, biopsy, and histopathologic guidelines for the evaluation of gastrointestinal inflammation in companion animals [published correction appears in J Vet Intern Med. 2010;24(3):796]. J Vet Intern Med. 2010;24(1):10\u201326. https:\/\/doi.org\/10.1111\/j.1939-1676.2009.0443.x.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"2910_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2307\/2528930","volume":"27","author":"DA Williams","year":"1971","unstructured":"Williams DA. A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics. 1971;27(1):103\u201317. 5547548. https:\/\/doi.org\/10.2307\/2528930.","journal-title":"Biometrics."},{"issue":"2","key":"2910_CR33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2307\/2556164","volume":"28","author":"DA Williams","year":"1972","unstructured":"Williams DA. The comparison of several dose levels with a zero dose control. Biometrics. 1972;28(2):519\u201331. PMID: 5037867. https:\/\/doi.org\/10.2307\/2556164.","journal-title":"Biometrics."}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-02910-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-021-02910-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-02910-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T08:04:45Z","timestamp":1622707485000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-021-02910-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2910"],"URL":"https:\/\/doi.org\/10.1186\/s12917-021-02910-0","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"24 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design was based on VICH GL43 Target Animal Safety Guidelines for Veterinary Pharmaceutical Products was conducted in accordance with the applicable sections of the United Kingdom Animals (Scientific Procedures) Act 1986, Amendment Regulations 2012 (the Act). The study protocol was approved by Covance Institutional Animal Care and Use Committee. Authors adhered to ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JH and MS are employees of Ecuphar Veterinaria SLU (Animalcare group), who sponsored the study. AG declares no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}